An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Stevanato Group Files Amendment No.1 to Its 2021 Annual Report on Form 20‑F/A
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) has filed Amendment No. 1 (Form 20-F/A) to its 2021 Annual Report with the SEC to add the Interactive Data File and provide additional information. This was filed on April 5, 2022, and the original Form 20-F was submitted on March 8, 2022.
Shareholders can access the Form 20-F/A at www.stevanatogroup.com. A printed copy is available upon request.
Positive
Enhances transparency with the filing of the amended Form 20-F/A.
Provides additional information in compliance with SEC regulations.
Negative
None.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced the filing of Amendment No. 1 (the “Form 20-F/A”) to its 2021 Annual Report on Form 20-F (the “Form 20-F”), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 8, 2022, to submit the Interactive Data File and to provide certain additional information as described in the explanatory note thereto.
Stevanato Group filed the Form 20-F/A with the SEC on April 5, 2022 (www.sec.gov). The Form 20-F/A will be available to shareholders and other interested parties at www.stevanatogroup.com. A printed copy can be obtained free of charge upon written request to the following email address ir@stevanatogroup.com.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit www.stevanatogroup.com
Forward-Looking Statements
This press release contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "future", "remain", "growing", "expect", "foreseeable", "expected", "to be", "includes", "estimated", "assumes", "would provide", and other similar terminology. Forward-looking statements contained in this press release include, but are not limited to, statements about: our future financial performance, including our revenue, operating expenses, and our ability to maintain profitability and operational and commercial capabilities; our expectations regarding the development of our industry and the competitive environment in which we operate; and our goals, strategies, and investment plans.
These forward-looking statements speak only as at their dates. Stevanato Group undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of these factors. Further, Stevanato Group cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statements.
For a description of certain additional factors that could cause Stevanato Group’s future results to differ from those expressed in any such forward-looking statements, see Item 3D. entitled "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2021, as amended, filed with the SEC.
